Close X
Attorney Spotlight

How did an interest in healthcare policy lead Robert Platt to a career in the law? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Trade Secrets Legislation Sails Through Senate

Firm Publication

Publications

April 5, 2016

On Monday, the U.S. Senate acted to strengthen legal protection against the theft of trade secrets, which costs U.S. business more than $300 billion a year. The Senate unanimously passed the Defend Trade Secrets Act (DTSA), sponsored by Senators Orrin Hatch (R-Utah) and Chris Coons (D-Delaware), which would open the federal courts to trade secrets litigation.

The DTSA would bring protection of trade secrets more in line with protection of other types of intellectual property, including copyright, trademark and patent.  Under current U.S. law, claims for misappropriation of trade secrets are the only types of intellectual property claims for which plaintiffs do not have a right to pursue in federal courts.

The DTSA provides remedies for trade secret misappropriation, including injunctive relief, compensatory damages, punitive damages and attorneys' fees in the event of willful or malicious misappropriation. Notably, the DTSA allows plaintiffs to seek ex parte government seizure of trade secrets to preserve evidence before notifying the defendant of a lawsuit.

The U.S. House of Representatives Subcommittee on Courts, Intellectual Property, and the Internet is currently considering an identical trade secrets bill.  Similar legislation was unsuccessfully attempted in 2014, but supporters of the DTSA, including many businesses and the U.S. Chamber of Commerce, hope that the unanimous Senate approval indicates the legislation will pass this session.  The DTSA will only become law upon passing both houses.


Bass, Berry & Sims will continue to monitor and provide updates on trade secrets legislation, as well as other legal developments that impact the protection of intellectual property rights.  For questions about the DTSA or protecting your intellectual property, please contact an attorney on our Intellectual Property team



Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.